Noble Financial Forecasts Zomedica FY2024 Earnings

Zomedica Corp. (NYSEAMERICAN:ZOM) – Analysts at Noble Financial issued their FY2024 earnings estimates for Zomedica in a research report issued to clients and investors on Monday, November 11th. Noble Financial analyst R. Leboyer expects that the company will earn ($0.05) per share for the year. Noble Financial has a “Strong-Buy” rating on the stock. Noble Financial also issued estimates for Zomedica’s Q4 2024 earnings at ($0.01) EPS, Q1 2025 earnings at ($0.01) EPS, Q2 2025 earnings at ($0.01) EPS, Q3 2025 earnings at ($0.01) EPS, Q4 2025 earnings at ($0.01) EPS, FY2025 earnings at ($0.03) EPS, FY2026 earnings at ($0.03) EPS and FY2027 earnings at ($0.03) EPS.

Zomedica Stock Down 6.7 %

ZOM opened at $0.14 on Thursday. The stock has a market cap of $135.23 million, a PE ratio of -2.30 and a beta of 1.06. Zomedica has a 52-week low of $0.12 and a 52-week high of $0.23.

Hedge Funds Weigh In On Zomedica

An institutional investor recently raised its position in Zomedica stock. Price T Rowe Associates Inc. MD lifted its stake in Zomedica Corp. (NYSEAMERICAN:ZOM) by 41.1% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 948,300 shares of the company’s stock after acquiring an additional 276,100 shares during the period. Price T Rowe Associates Inc. MD owned approximately 0.10% of Zomedica worth $139,000 at the end of the most recent reporting period. 8.95% of the stock is currently owned by hedge funds and other institutional investors.

About Zomedica

Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company offers diagnostic products comprising TRUFORMA Bulk Acoustic Wave point of care diagnostic platform; TRUVIEW, a digital cystoscopy platform that offers automated slide preparation within the instrument; and VetGuardian, a zero-touch vital signs remote monitoring system.